Clinical trials: Leucovorin
Colorectal Cancer Stage IV
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective in first line as the same regimen given continuously, resulting in a Time to Treatment Failure (TTF) not inferior to that obtained…
- Trial name
- IMPROVE-2 (NCT06509126)
- Testing
- Panitumumab, Irinotecan, 5-fluorouracil
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute, Naples
Chemotherapy, Colorectal Cancer
Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients
Mucositis is a common and clinically significant side effect of both anticancer chemotherapy and radiation therapy that can affect any portion of the gastrointestinal tract.
- Conditions
- Chemotherapy, Colorectal Cancer, Intestinal Mucositis, Oral Mucositis
- Trial name
- NCT05871333
- Testing
- Losartan 50mg Tab
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Pancreatic Cancer
A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer
Induction chemotherapy will be administered every 2 weeks for 6 cycles (about 3 months). Patients who have radiological evidence of progressive disease will be shifted to salvage chemotherapy.
- Trial name
- NCT00149578
- Testing
- Gemcitabine Oxaliplatin 5FU and Leucovorin
- Where
- 2 sites in Taiwan
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Colorectal Cancer
Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery
RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00016133
- Testing
- BCG vaccine, autologous tumor cell vaccine, fluorouracil
- Where
- 2 sites in United States
- Sponsor
- Intracel
Progression-Free Survival
Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy
To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin
- Trial name
- NCT06826092
- Testing
- Metformin Pill, FOLFIRI plus target therapy only
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Lymphoma
S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00041132
- Testing
- filgrastim, rituximab, cyclophosphamide
- Volunteers
- 56 people
- Sponsor
- SWOG Cancer Research Network
Gastric Cancer
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
After the initial diagnostic laparoscopy the Control group patients undergo 6 courses of polychemotherapy according to the FLOT scheme; the examination is carried out every 3 courses (after the 3rd and the 6th courses) with the…
- Trial name
- NCT06313801
- Testing
- Docetaxel, Oxaliplatin, Calcium folinate
- Where
- Russia
- Volunteers
- 106 people
- Sponsor
- Nizhny Novgorod Regional Clinical Oncology Center
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00039611
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 19 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00020488
- Testing
- FOLFIRI regimen, fluorouracil, irinotecan hydrochloride
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE.
- Trial name
- NCT02220088
- Testing
- TAI of FOLFOX, Sorafenib
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Sun Yat-sen University
Unspecified Adult Solid Tumor, Protocol Specific
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of alvocidib when given together with oxaliplatin, fluorouracil, and leucovorin calcium in treating patients with advanced solid tumors.
- Trial name
- NCT00080990
- Testing
- alvocidib, fluorouracil, oxaliplatin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Secondary Central Nervous System Lymphoma
R-MTX-zanbrutinib in Secondary CNS Lymphoma
Secondary central nervous system lymphoma (SCNSL) occurred in about 5% of patients with diffuse large B-cell lymphoma (DLBCL). The prognosis of SCNSL is very poor.
- Trial name
- NCT05398224
- Testing
- Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking University
Oncology
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
This is an open-label, multi-center, multi-national, non-randomized rollover study designed to allow continued access to napabucasin for patients who have participated in a Boston Biomedical-sponsored study and are being treated…
- Trial name
- NCT04299880
- Testing
- Napabucasin, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 7 people
- Sponsor
- Sumitomo Pharma America, Inc.
Colorectal Neoplasms
FOLFOXIRI-based HAIC Combined With Fuquintinib as Late-line Treatment in Patients With CRLM：A Phase 2 Single-Arm Clinical Trial
This study was a phase 2, single-arm, single-center clinical trial in which previously treated patients with unresectable colorectal cancer liver metastases.
- Trial name
- HAIC，CRLM (NCT07024537)
- Testing
- FOLFOXIRI-based HAIC+Fuquinitinib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Meng Qiu
Metastatic Pancreatic Cancer
Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients
The aim of this study is to evaluate the efficacy of sequential treatment (Gabrinox) comprising Gembrax regimen (Gemcitabine -Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) compared to folfirinox…
- Trial name
- GABRINOX2 (NCT05065801)
- Testing
- GEMBRAX/FOLFIRINOX Arm A, FOLFIRINOX Arm B
- Where
- 8 sites in France
- Volunteers
- 162 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Uterine Neoplasms
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
Primary: To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline. Secondary: To assess the safety and tolerability of oxaliplatin To assess time to progression and…
- Trial name
- NCT00782041
- Testing
- Oxaliplatin, 5-FluoroUracil, Folinic acid
- Where
- Thailand
- Volunteers
- 11 people
- Sponsor
- Sanofi
Colorectal Cancer Metastatic, mCRC
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
- Trial name
- NCT03563157
- Testing
- Aldoxorubicin Hydrochloride, ALT-803, ETBX-011
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- ImmunityBio, Inc.
Hepatocellular Carcinoma
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with hepatocellular…
- Trial name
- NCT03468231
- Testing
- Sorafenib, HAIC of FOLFOX, HAIC of OXA
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced…
- Trial name
- NCT05702229
- Testing
- Rilvegostomig, Volrustomig, FOLFOX
- Where
- 44 sites in United States, China and 5 more
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Colorectal Peritoneal Carcinomatosis
Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis
The purpose of this study is to see if there is a difference in survival between two different treatment strategies for colorectal peritoneal surface disease.
- Trial name
- NCT01524094
- Testing
- Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin), Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)
- Where
- Sweden
- Volunteers
- 49 people
- Sponsor
- Uppsala University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.